Treatment of Molluscum Contagiosum in Pediatric Patients
For most children with molluscum contagiosum, watchful waiting remains a reasonable first-line approach, but when treatment is pursued, topical therapies including 10% potassium hydroxide, 0.7% cantharidin, or salicylic acid + lactic acid 16.7% demonstrate the strongest evidence for efficacy in pediatric patients.
Treatment Decision Framework
When to Treat vs. Observe
The condition spontaneously resolves in 6-12 months in most cases, though complete resolution can take up to 4 years 1. However, treatment should be considered when:
- Lesions are cosmetically bothersome or in highly visible locations
- Underlying skin conditions like eczema are present
- Symptoms include pain, itching, or redness
- Risk of transmission to others is a concern (e.g., athletes, household contacts)
- Associated conjunctivitis develops from eyelid lesions 2
Critical caveat: No single intervention has been shown to be convincingly effective, and natural resolution remains a valid management strategy 3.
Evidence-Based Treatment Options
First-Line Topical Therapies (Strongest Evidence)
10% Potassium Hydroxide: Demonstrates superior efficacy versus placebo (RR 3.05,95% CI 1.77-5.24) with robust multi-study evidence 4. Both forms of treatment (KOH and cryotherapy) appear to have similar efficacy in children 1.
0.7% Cantharidin (FDA-approved): Shows high efficacy (RR 3.25,95% CI 1.39-7.58) 4. Open-label studies indicate effectiveness, though one small RCT (29 patients) showed improvement greater than placebo but not statistically significant 1. Recent FDA approval provides additional treatment option with meaningful lesion clearance (>50%) within 6 weeks to 3 months 5.
Salicylic acid + lactic acid 16.7%: Demonstrates superior efficacy (RR 3.16,95% CI 1.81-5.52) with the highest SUCRA ranking (86.0%) among multi-study treatments 4.
Cryotherapy with Liquid Nitrogen
Used for cosmetically bothersome lesions or patients with eczema 1. Important warning: May cause postinflammatory hyperpigmentation or, uncommonly, scarring 1. This risk is particularly relevant in darker-skinned children.
Imiquimod 5% - NOT Recommended
High-quality evidence demonstrates imiquimod is ineffective: Multiple large unpublished studies show no benefit over vehicle (placebo) for:
- Short-term cure at 12 weeks (RR 1.33,95% CI 0.92-1.93)
- Medium-term cure at 18 weeks (RR 0.88,95% CI 0.67-1.14)
- Long-term cure at 28 weeks (RR 0.97,95% CI 0.79-1.17)
Additionally, imiquimod causes significantly more application site reactions (RR 1.41, NNTH = 11) and severe reactions (RR 4.33) 3.
However, one 2022 case-control study with personalized dosing (once daily until inflammatory reaction, then suspend until resolved, repeat cycle) showed all but one patient lesion-free by week 20 versus persistent lesions in untreated controls 6. This contradicts the high-quality RCT evidence and should be interpreted cautiously.
Berdazimer Gel 10.3% (FDA-approved)
Newer FDA-approved therapy demonstrating favorable safety profile for pediatric patients with meaningful lesion clearance (>50%) within 6 weeks to 3 months 5. Provides additional option when other treatments fail or are not tolerated.
Special Considerations
Eyelid/Periocular Lesions
When molluscum lesions occur on eyelids causing conjunctivitis or keratitis, treatment to remove the lesions is indicated in symptomatic patients 2, 7, 2. Options include:
- Incision and curettage (aggressive enough to cause bleeding)
- Simple excision
- Excision and cautery
- Cryotherapy
The conjunctivitis may require weeks to resolve after lesion elimination 2, 7, 2. In patients with multiple lesions, identify and treat nascent lesions to reduce recurrence risk.
Athletes/Contact Sports
For wrestlers and contact sport athletes, lesions should be covered or athletes excluded from competition until lesions resolve to prevent transmission 1.
Treatment Algorithm
- Assess need for treatment based on symptom burden, location, underlying conditions, and transmission risk
- If observation chosen: Reassure family that spontaneous resolution typically occurs in 6-12 months
- If treatment pursued:
- First choice: 10% potassium hydroxide OR salicylic acid + lactic acid 16.7% OR 0.7% cantharidin
- Alternative: Cryotherapy (but warn about pigmentation risk in darker skin)
- For resistant cases: Consider berdazimer gel 10.3%
- Avoid: Imiquimod 5% (proven ineffective in high-quality trials)
- For eyelid lesions with conjunctivitis: Physical removal (curettage, excision, or cryotherapy)
Common Pitfalls to Avoid
- Do not use imiquimod based on the robust RCT evidence showing lack of efficacy despite one positive observational study
- Warn families about scarring risk with cryotherapy, especially in children with darker skin tones
- Do not promise rapid resolution - even with treatment, clearance takes weeks to months
- Screen for immunocompromised state if lesions are large, multiple, or unusually persistent (may indicate HIV or other immune deficiency) 2, 7